Vaccibody to participate at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days - Vaccibody.com
2937
post-template-default,single,single-post,postid-2937,single-format-standard,bridge-core-2.4.3,qode-page-transition-enabled,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-25.7,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Vaccibody to participate at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days

Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that its Chief Executive Officer, Michael Engsig and Chief Innovation and Strategy Officer, Agnete Fredriksen, will participate in a fireside chat at Guggenheim Securities’ 2nd Annual Vaccine and Infectious Disease Days on October 6, 2021 at 3.30 pm EDT / 9.30 pm CEST.

A link to the live fireside chat may be found here: https://kvgo.com/guggenheim/vaccibody-oct-2021